<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01151098</url>
  </required_header>
  <id_info>
    <org_study_id>BUP3201S</org_study_id>
    <nct_id>NCT01151098</nct_id>
  </id_info>
  <brief_title>Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study</brief_title>
  <official_title>An Open-Label, Multi-Center, Titration Study to Establish the Long-term Safety and Tolerability of Buprenorphine Transdermal Delivery System (BTDS) 5 mg, 10 mg, and 20 mg in Patients With Chronic Non-Malignant Pain Syndromes Responsive to Opioid Combination Therapy - a 28-Week Extension Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Purdue Pharma LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Purdue Pharma LP</source>
  <brief_summary>
    <textblock>
      The objective of this study was to evaluate the long-term safety and tolerability of 7-day
      BTDS in a 28-week open-label extension phase in subjects with chronic nonmalignant pain
      syndromes whose pain had been previously controlled by oral opioid combination therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Upon entering the extension phase (BUP3201S), subjects will receive BTDS 5, regardless of
      their dose level at discontinuation or completion of the BUP3201 core study. Subjects are
      allowed to titrate after 48 hours to BTDS 10 or 20 that provided stable pain control with
      minimal tolerability problems. Additional medical therapies are permitted if necessary, and
      there is no restriction on concomitant analgesic medications. The subjects have weekly visits
      for 4 consecutive weeks, and every 4 weeks thereafter, until the end of the scheduled
      extension phase.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">February 2002</completion_date>
  <primary_completion_date type="Actual">February 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) as a Measure of Safety.</measure>
    <time_frame>28 weeks</time_frame>
    <description>Safety was assessed using reports of all new adverse events (AEs) that occurred after the first application of a patch during the extension phase were recorded.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">189</enrollment>
  <condition>Chronic Nonmalignant Pain</condition>
  <arm_group>
    <arm_group_label>BTDS 5, 10 or 20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buprenorphine transdermal patch</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine transdermal patch</intervention_name>
    <description>Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear</description>
    <arm_group_label>BTDS 5, 10 or 20</arm_group_label>
    <other_name>Butransâ„¢</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Include:

          -  Subjects of either sex aged 18 years or older.

          -  Subjects who have completed or discontinued the double-blind evaluation phase of study
             BUP3201 are eligible to continue to receive open-label BTDS in the extension.

        Exclusion Criteria:

        Include:

          -  Subjects currently receiving daily morphine or oxycodone (mono-therapy).

          -  Subjects who are discontinued from BUP3201 due to adverse events.

          -  Subjects who are scheduled for surgery of the disease site (e.g. major joint
             replacement surgery) or any other major surgery which would fall within the study
             period.

        Refer to core study for additional inclusion/exclusion information.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arizona Research Center Inc.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consultants Inc</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <zip>06611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Bay Medical Research Inc</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Research Deland</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Research Inc,</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Coast Research, LLC</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Coast Research LLC</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Medicine Associates</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pain Management &amp; Rehabilitation</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Center for Headache and Pain</name>
      <address>
        <city>Crestview Heights</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westside Family Medical Center PC</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Arthritis Clinic</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornerstone Research Care</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALL-TRIALS Clinical Research LLC</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Research Solutions</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wasatch Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Management</name>
      <address>
        <city>New Berlin</city>
        <state>Wisconsin</state>
        <zip>53151</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://app.purduepharma.com/xmlpublishing/pi.aspx?id=b</url>
    <description>Product Information</description>
  </link>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2010</study_first_submitted>
  <study_first_submitted_qc>June 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2010</study_first_posted>
  <results_first_submitted>July 29, 2010</results_first_submitted>
  <results_first_submitted_qc>August 30, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 23, 2010</results_first_posted>
  <last_update_submitted>September 5, 2012</last_update_submitted>
  <last_update_submitted_qc>September 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic nonmalignant pain</keyword>
  <keyword>Opioid</keyword>
  <keyword>Transdermal</keyword>
  <keyword>Butrans (BTDS)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>16-Apr-2001 (first patient first visit) 27-Feb-2002 (last patient last visit). The extension phase of study was conducted at 20 sites in the US Baseline Period: and 18 sites in the UK.</recruitment_details>
      <pre_assignment_details>Adult subjects aged â‰¥ 18 years, with chronic nonmalignant pain, controlled on oral opioid therapy. Subjects in the US who participated in the BUP3201 core study and met the criteria per Amendment 2, and subjects in the UK who participated in the BUP3201 core and met the inclusion/ exclusion criteria, were able to participate in the extension.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Total Extension Phase</title>
          <description>Buprenorphine transdermal patches (BTDS 5, 10 or 20) applied for 7-day wear.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="189">Extension Safety Population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Extension Phase (BTDS 5, 10 or 20)</title>
          <description>Buprenorphine transdermal patches (BTDS 5, 10 or 20) applied for 7-day wear.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="189"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.2" spread="12.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs) as a Measure of Safety.</title>
        <description>Safety was assessed using reports of all new adverse events (AEs) that occurred after the first application of a patch during the extension phase were recorded.</description>
        <time_frame>28 weeks</time_frame>
        <population>The Extension Safety population (N = 189) includes all subjects who were exposed to BTDS during the Open-label Extension Phase and provided at least 1 valid safety assessment after exposure to BTDS during the Open-label Extension Phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Total Extension Phase</title>
            <description>Buprenorphine transdermal patches (BTDS 5, 10, or 20) applied for 7-day wear.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) as a Measure of Safety.</title>
          <description>Safety was assessed using reports of all new adverse events (AEs) that occurred after the first application of a patch during the extension phase were recorded.</description>
          <population>The Extension Safety population (N = 189) includes all subjects who were exposed to BTDS during the Open-label Extension Phase and provided at least 1 valid safety assessment after exposure to BTDS during the Open-label Extension Phase.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Other Adverse Events in â‰¥ 4.5% of Subjects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events that occurred after administration of the first dose of study drug on or before the final visit were reported and up to 30 days after the end of the trial.</time_frame>
      <desc>Adverse Events were obtained through spontaneous reports and subject interview.</desc>
      <group_list>
        <group group_id="E1">
          <title>Total Extension Phase</title>
          <description>Buprenorphine transdermal patches (BTDS 5, 10 or 20) applied for 7-day wear.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>COSTART 5.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Myocardial infarct</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia - Death</sub_title>
                <description>DEATH - Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Joint disorder</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Carcinoma</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Lymphoma-like reaction</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Ovarian carcinoma</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Uterine fibroids enlarged</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Pulmonary embolus</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorder</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4.50</frequency_threshold>
        <default_vocab>COSTART 5.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental injury</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema at site</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Pruritus at site</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Rash at site</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Other site reaction</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Leader, Executive Medical Director</name_or_title>
      <organization>Purdue Pharma L.P.</organization>
      <phone>800-733-1333 OR 800-745-7445</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

